Direxion Shares ETF Trust Direxion Daily LLY Bear 1X ETF

ELIS

Börsenwert 2,4 Mio. $

New York, New York, March 13, 2026 (GLOBE NEWSWIRE) -- Closures Due to Limited Interest Since Launch Due to their inability to attract sufficient investment assets, the Board of Trustees of the Direxion Shares ETF Trust has decided to liquidate and close ten ETFs (each, a “Fund” and collectively, the “Funds”), based on the recommendation of the Funds' adviser, Rafferty Asset Management, LLC. The Board concluded that liquidating and closing the Funds would be in the best interest of the Funds and their shareholders.

As the largest publicly traded U.S. healthcare enterprise, Eli Lilly & Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year.

2025 has so far been a big year for leveraged ETFs. I wrote a research note on leveraged ETFs earlier this year (read more here) where I discussed some trends in the leveraged ETF market.

Getting stuck in sideways purgatory can leave traders flummoxed. Should they cut bait or ride out the position in hopes that it will eventually trend upwards?

On Wednesday, Direxion expanded its suite of leveraged and inverse ETF products with the launch of four new funds.  Each of the new Direxion ETFs offers leveraged or inverse exposure to a single stock's daily price performance.